282 results
424B5
GTBP
GT Biopharma Inc
23 May 24
Prospectus supplement for primary offering
6:04am
, the issuance by us of equity or debt securities pursuant to acquisitions or strategic transactions approved by a majority of our disinterested directors, where
8-K
EX-4.1
GTBP
GT Biopharma Inc
23 May 24
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:02am
market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest … by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which
8-K
EX-10.1
GTBP
GT Biopharma Inc
23 May 24
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:02am
stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members … or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities are issued as “restricted
8-K
GTBP
GT Biopharma Inc
23 May 24
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:02am
by a majority of the Company’s disinterested directors, where not for the purpose of raising capital, or certain other compensatory issuances
DEFR14A
fkh0cnj
5 May 23
Revised proxy
5:28pm
8-K
EX-3.1
i3b5 9aul5did2a
9 Nov 22
Amendments to Articles of Incorporation or Bylaws
5:00pm
DEFA14A
o0o0z61og prny6cjj
4 Oct 22
Additional proxy soliciting materials
4:50pm
8-K
f8yx865a1jyv sf
4 Oct 22
GT Biopharma Announces Adjournment of Special Shareholders Meeting
4:49pm